title: Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.
abstract: BACKGROUND
  Fibrolamellar carcinoma is a rare and poorly understood malignancy that affects the young in the absence of underlying liver disease. Despite reported small review series, the literature lacks large retrospective studies that may help in understanding this disease.
  
  
  METHODS
  Medical record review was undertaken for all patients histopathologically diagnosed with fibrolamellar carcinoma, seen at Memorial Sloan-Kettering Cancer Center, the University of California San Francisco, and Johns Hopkins Hospital from 1986 to 2011. Demographic, clinical, pathologic, and treatment data were recorded. Overall survival was estimated by using Kaplan-Meier methods. The impact of different clinicopathologic variables on survival was assessed with Cox regression models.
  
  
  RESULTS
  Ninety-five patients were identified. Median age was 22 years, 86% were Caucasian, and 50% presented with stage IV disease. There were more females than males (58% vs. 42%). Seventy-seven percent of the patients underwent surgical resection and/or liver transplantation; of these 31.5% received perioperative therapy. Patients with unresectable disease, including 8 patients treated in clinical trials, were treated with chemotherapy, occasionally given with interferon or biologic agents. Ten patients received sorafenib, and 7 received best supportive care. Median survival was 6.7 years. Factors significantly associated with poor survival were female sex, advanced stage, lymph node metastases, macrovascular invasion, and unresectable disease.
  
  
  CONCLUSIONS
  The clinicopathologic characteristics and survival outcomes from this dataset are consistent with those reported in the literature. Surgical resection and disease extent were confirmed as important predictors of survival. The possibility of a negative association between female sex and prognosis could represent a clue as to future therapeutic strategies.
authors.affiliation: Memorial Sloan-Kettering Cancer Center and Weill Medical College at Cornell University New York, NY.
authors.forename: Celina S
authors.initials: CS
authors.lastname: Ang
authors.forename: R Katie
authors.initials: RK
authors.lastname: Kelley
authors.forename: Michael A
authors.initials: MA
authors.lastname: Choti
authors.forename: David P
authors.initials: DP
authors.lastname: Cosgrove
authors.forename: Joanne F
authors.initials: JF
authors.lastname: Chou
authors.forename: David
authors.initials: D
authors.lastname: Klimstra
authors.forename: Michael S
authors.initials: MS
authors.lastname: Torbenson
authors.forename: Linda
authors.initials: L
authors.lastname: Ferrell
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Pawlik
authors.forename: Yuman
authors.initials: Y
authors.lastname: Fong
authors.forename: Eileen M
authors.initials: EM
authors.lastname: O'Reilly
authors.forename: Jennifer
authors.initials: J
authors.lastname: Ma
authors.forename: Joseph
authors.initials: J
authors.lastname: McGuire
authors.forename: Gandhi P
authors.initials: GP
authors.lastname: Vallarapu
authors.forename: Ann
authors.initials: A
authors.lastname: Griffin
authors.forename: Francesco
authors.initials: F
authors.lastname: Stipa
authors.forename: Marinela
authors.initials: M
authors.lastname: Capanu
authors.forename: Ronald P
authors.initials: RP
authors.lastname: Dematteo
authors.forename: Alan P
authors.initials: AP
authors.lastname: Venook
authors.forename: Ghassan K
authors.initials: GK
authors.lastname: Abou-Alfa